OHM20, seeing as you are up-periscope at the moment, and speaking of the HIV monotherapy trial, with reference to current company protocols under development it strikes me that monotherapy overlap with NASH/NAFLD would definitely qualify as fast track and unmet need, potentially breakthrough designation…priority target acquired. The question I have is whether you have given any thought to 700 mg dosing for monotherapy reflected against clearer NASH results at 350mg. Recognizing the need to be more bullet-proof for monotherapy the higher dose is going to prevail in the protocol. Do you think the 700 mg for NASH can be made to sing by things like haplotype inclusion criteria, upping number to treat or other factors? I’m sure Recknor is in the weeds with this, and hope they give us some specifics at the ASM…would love to do a Spock mind-meld with that guy. Any thoughts?